Bringing the fundamentals into focus…
Back to Ultragenyx Pharmaceutical Inc.
How Ultragenyx Pharmaceutical Inc. stacks up
RARE · against 1,216 other Healthcare companies
Growth
63/ 100
Above the middle of the pack.
Ranked #445 of 1,217 · scores higher than 63% of peers
Bars: peers in each 10-point band of the growth score122 peers with a growth score of 60–69, including RARE · Click a bar to see the companies
Why growth scores 63?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its 3-year revenue growth and revenue growth, which are stronger than most Healthcare peers.
- The loss per share widened. Earnings per share growth: — vs peer median 9.8%
- faster revenue growth over the last year: stronger than 76% of peers. Revenue growth: 17.5% vs peer median 6.1%
- faster revenue growth over three years: stronger than 81% of peers. 3-year revenue growth: 21.2% vs peer median 5.8%
Metric by metric
Position: dot = RARE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RARE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 1,243 reported | 17.5% | 6.1% | 76% | 33% | |
| Earnings per share growthHigher is better · 682 reported | Not reported | 9.7% | — | — | 33% |
| 3-year revenue growthHigher is better · 1,192 reported | 21.2% | 5.8% | 81% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around RARE| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 464M USD | 100 | 53 | |
| 3 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 3 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 3 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 445 | 866M EUR (≈$952M) | 63 | 65 | |
| 445 | 5.1B USD | 63 | 54 | |
| 445 | 11.1B BRL (≈$2.0B) | 63 | 60 | |
| 445 | 26.0B BRL (≈$4.7B) | 63 | 60 | |
| 445 | 1.6B USD | 63 | 24 | |
| 458 | 8.2B CNY (≈$1.2B) | 62 | 50 | |
| 458 | 2.05T KRW (≈$1.5B) | 62 | 81 | |
| 458 | 3.9B CNY (≈$549M) | 62 | 61 | |
| 458 | 272M HKD (≈$35M) | 62 | 59 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score